Navigation Links
Tris Pharma's New Tool Fights Against Prescription Drug Abuse
Date:11/12/2008

SOUTH BRUNSWICK, N.J., Nov. 12 /PRNewswire/ -- Tris Pharma, a privately owned, specialty pharmaceutical company, today unveiled a key component in the nation's fight against opioid abuse. Its new drug delivery platform, NoBuse(TM), offers a technology by which companies can deliver effective pain relief or ADHD products that are nearly impervious to abuse.

In the United States, narcotic pain relievers have fueled a dangerous epidemic. One in five teens has abused a prescription pain medication(1) and emergency room visits associated with these drugs have increased 163 percent since 1995(2). The situation has created barriers to access for patients suffering from real pain: Doctors are more reticent to prescribe opioids, and regulators have refused to allow new analgesics on the market unless they have the highest forms of abuse deterrence measures in place.

But Tris Pharma's NoBuse(TM) technology allows companies to provide pain relief responsibly. "In the current environment where opioid abuse has become such a problem, companies must first consider safeguarding their drugs if they want to reach patients in need," says Ketan Mehta, CEO and Founder of Tris Pharma. "There's no reason for patients to suffer needlessly when NoBuse(TM) provides such an effective option for abuse prevention."

There is a perception that conventional sustained release formulations are less prone to abuse then immediate-release formulations. However, users can easily extract the full 12-24 hour dose from existing sustained-release preparations for immediate consumption and then snort, swallow, or inject it- all of which provides users a "high" and which can be extremely dangerous when larger than intended doses are taken.

The NoBuse(TM) delivery system is engineered to prevent abuse on a physical level without the need for additional ingredients. NoBuse(TM) employs a technique where the drug is complexed to very fine polymeric particles and coated with a highly flexible non-breakable film resulting in particles that are extremely difficult to extract drug from-even after crushing the tablet or dissolving it in alcohol.

"Abuse of prescription drugs is a fast-growing problem-being able to limit this liability is a real benefit to society," says Thomas Newton, MD, Professor of Psychiatry at the Baylor College of Medicine. "Other methods can be breached-but the data for NoBuse(TM) shows that it is virtually impossible for abusers to get around. I also like the fact that the abuse deterrence is not contingent on the patient being forced to take added active ingredients such as the antagonist naloxone. The vast majority of patients aren't abusers and there is no reason for them to ingest an additional drug they don't need."

The technology works across a range of oral dosage forms including tablets, liquid suspensions, orally disintegrating tablets, and drug strips. It can also be used to formulate an immediate-release product with a built-in abuse deterrent. In doing so, Tris Pharma's NoBuse(TM) technology provides important value and a competitive advantage against competing delivery technologies.

About Tris Pharma, Inc.

Tris Pharma, Inc. is a specialty drug delivery technology company. Tris specializes in controlled release dosage forms for liquid, solid and orally disintegrating tablets; abuse-deterrent technology; and bioavailability enhancement of poorly absorbed drugs. Through its pharma partners, Tris has more than 30 products in development, submission or on market. Tris' research and manufacturing facilities are located in central New Jersey, USA. For more information, please visit http://www.trispharma.com

(1) Partnership for a Drug Free America

(2) "Prescription for Danger," produced by the Office of National Drug Control Policy, January 2008


'/>"/>
SOURCE Tris Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services
2. Pharmasset to Webcast an Investor Event from the AASLD Meeting
3. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
6. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
7. Pharmassets Underwriters Release Shares from Lock-Up
8. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
9. Sperm Donor Fights for His Rights as a Father in U.S. Supreme Court
10. Compound in Red Wine Fights Ravages of Age
11. Experimental Drug Fights Multiple Sclerosis Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 , ... The annual time ... Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are ... or prescription drug plan (Part D) need to make changes during this period order ...
(Date:12/2/2016)... ... ... More than half of American teens report losing their virginity before they ... child about sex related topics, less than 60 percent spoke about deeper themes like ... launch of its second edition of the “Sexual Wellness” campaign, aiming to address the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs ... properties including its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) ... Nothing Water has been available in several ShopRite and FoodTown stores in NJ and ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
(Date:11/30/2016)... Northridge, CA (PRWEB) , ... November 30, 2016 ... ... Elyson, announce that they now offer a comprehensive in-house dental plan for all ... dentists have developed a plan that gives patients a number of perks, including ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... , , Drug delivery ... value of drug delivery technologies and the anticancer drugs are difficult ... organs involved and the types of cancer as well as according ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories (das "Unternehmen"), ... diesem Monat seinen  INSTI HIV-Selbsttests  in einer Version mit geringeren Kosten einzuführen.  ... ... New: INSTI Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444833 ) ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Detachable Coils 2017 - MedCore" report to their offering. ... , , ... and cerebral blood vessel malformations. The detachable coil embolization treatment of cerebral ... An aneurysm is a weakened area in the wall of an artery ...
Breaking Medicine Technology: